ONL Therapeutics Secures $15 Million Seed Funding to Revolutionize Retinal Disease Treatment

ONL Therapeutics (ONL), a pioneering clinical-stage biopharmaceutical company dedicated to safeguarding and enhancing vision for patients with retinal diseases, is excited to announce the successful completion of a $15 million funding round. This financial milestone represents a significant step forward in ONL's mission to develop groundbreaking therapeutics aimed at preventing the blindness caused by retinal cell death—one of the leading causes of visual impairment worldwide. The funding will primarily be allocated towards advancing ONL’s lead therapeutic candidate, ONL1204, a first-in-class small peptide Fas inhibitor designed to target the critical Fas pathway responsible for the death of retinal cells. Currently, ONL1204 is being formulated as an ophthalmic solution to address retinal detachment, a serious condition recognized by the FDA with orphan drug designation. Additionally, the raised capital will bolster the company's efforts in further clinical trials exploring ONL1204’s efficacy in treating geographic atrophy linked to age-related macular degeneration and other prevalent retinal conditions such as glaucoma. With this infusion of capital, ONL Therapeutics aims to accelerate its innovative research and development processes, ultimately bringing transformative therapies to patients suffering from debilitating eye diseases. As ONL continues to forge ahead, it remains committed to revolutionizing the treatment landscape for retinal disorders and improving the quality of life for millions struggling with vision loss.